Lumos Pharma, Inc.

LUMO · NASDAQ
Analyze with AI
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Activities
Net Income-$34,034-$31,062-$30,430-$5,663
Dep. & Amort.$44$49$203$584
Deferred Tax$0$0$0-$9,500
Stock-Based Comp.$2,322$2,320$2,879$1,074
Change in WC$965$2,096-$2,314-$3,618
Other Non-Cash-$392-$26$14-$5,874
Operating Cash Flow-$31,095-$26,623-$29,648-$22,997
Investing Activities
PP&E Inv.$0-$21-$30-$30
Net Acquisitions$0$0$0$84,179
Inv. Purchases-$7,378-$11,337$0$0
Inv. Sales/Matur.$18,120$0$0$0
Other Inv. Act.$0-$11,337$26,000$32,500
Investing Cash Flow$10,742-$11,358$25,970$116,649
Financing Activities
Debt Repay.$0$0$0-$27
Stock Issued$725$0-$78$116,949
Stock Repurch.-$1,310-$675-$114$0
Dividends Paid$0$0$0$0
Other Fin. Act.$9-$146-$114$102
Financing Cash Flow-$576-$821-$192$75
Forex Effect$0$0$0$0
Net Chg. in Cash-$20,929-$38,802-$3,870$93,727
Supplemental Information
Beg. Cash$56,007$94,809$98,679$4,952
End Cash$35,078$56,007$94,809$98,679
Free Cash Flow-$31,095-$26,644-$29,678-$23,027